glp-1 shortage over Antagonists Increase Plan Drug Spend - What's Next National Hispanic Medical Association |

Side Effect Update for GLP-1 Receptor Agonists The FDA is requiring that Glucagon-like peptide-1 (GLP-1) drug labels include updated warnings about the risk of serious kidney injury associated with the drugs gastrointestinal effects

United Healthcare : Covers tirzepatide with prior authorization for eligible patients

While semaglutide alone rarely causes hypoglycemia, combining these medications with insulin or sulfonylureas increases that risk

Brand-name GLP-1 medications can list for more than $1,000 a month, making smaller doses an appealing option for patients paying out of pocket

Metabolism 127 , 154937 (2022) I